Chronic myelogenous leukemia (CML) might be treated by drugs that inhibit the dipeptide transporter Slc15A2 – a finding based on metabolomic and transciptomic studies by the group of Nakahito NAKAHIRO at Hiroshima University’s A-bomb Radiological Science Institute. Drugs targeting this transporter might help to treat CML patients who have become resistant to tyrosine kinase inhibitors. A physician-led clinical study is in preparation.

Communication at 12th Translational Workshop for Molecular Target Therapy of Cancer, January 17, 2017